Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
80 hedge funds and large institutions have $189M invested in Avadel Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 13 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
0.84% less ownership
Funds ownership: 45.01% → 44.18% (-0.84%)
5% less call options, than puts
Call options by funds: $1.04M | Put options by funds: $1.09M
4% less funds holding
Funds holding: 83 → 80 (-3)
13% less capital invested
Capital invested by funds: $216M → $189M (-$27.6M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$13.2M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$7.48M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.85M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.67M |
| 5 |
AC
Armistice Capital
New York
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$9.64M |
| 2 |
NC
Nexthera Capital
New York
|
-$4.15M |
| 3 |
Morgan Stanley
New York
|
-$3.78M |
| 4 |
Renaissance Technologies
New York
|
-$3.19M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.1M |
AVDL Hedge Fund Activity: Q1 2018 in Review
80 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2018, worth a combined $189M — down 13% from $216M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of AVDL and 10 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 26 added.
The largest buyer was Brandes Investment Partners, adding an estimated $13.2M. The largest seller was Perceptive Advisors, cutting an estimated $9.64M.
- 80 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2018, down from 83 in Q4 2017.
- Funds reported $189M of Avadel Pharmaceuticals stock for Q1 2018, down 13% quarter-over-quarter.
- 10 funds opened new Avadel Pharmaceuticals positions in Q1 2018 and 13 closed out, a net change of -3 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2018 was Brandes Investment Partners, an estimated $13.2M added.
- The largest Avadel Pharmaceuticals seller in Q1 2018 was Perceptive Advisors, an estimated $9.64M sold.
Based on aggregated 13F filings for Q1 2018.